Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. NSCLC develops when abnormal cells in the lung grow uncontrollably, forming tumors that can impair lung function, spread to nearby tissues, and metastasize to other parts of the body. NSCLC is generally divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype has distinct characteristics, and the progression of NSCLC varies based on factors like cancer stage, location, and individual health conditions.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
Read more...
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients
Read more...
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Read more...